EP213/#937 PARP inhibitor maintenance in platinum-sensitive ovarian cancer: a single-center real-world experience

Objectives

Poly (ADP-ribose) polymerase (PARP) Inhibitors are used as a maintenance strategy and significantly improve PFS in platinum-sensitive ovarian cancer (PSOC) maintenance. There is a paucity of clinical data from the Indian subcontinent regarding the Olaparib in the PSCO setting

Methods

This is a retrospective analysis of PSOC patients treated with PARPi maintenance at the Medical Oncology Clinic. Data analyzed by SPSS statistics software, IBM Corp.

Results

Between Sep 2017 and Jan 2022, 64 patients were analyzed. And 15(23%) are still on PARPi therapy at cutoff. The median age was 50.0 years (range 25.0–66.0). Baseline stage at diagnosis stage IB 1(1%), IC 2 (3%) IIB 1 (1%), IIIC 25(39%), IV 35 (54%). A majority of the patients were assessed for homologous recombinant repair gene (HRR) mutation status, and 19 (29.6%) were mutated. Median progression-free survival was (9.3 months [IQR 7–13.3 m). The median PFS of patients receiving one and >1 line of therapies is 12.6 (IQR 9–19.6) and 8.6 (IQR 6–13) months, respectively. Anemia 14 (21%), Vomiting 10(16%), fatigue eight (12%), and thrombocytopenia 10 (15%) were the most common adverse events of grade 3 or more severity. Two patients developed MDS/AML. Results of patients on PARPi therapy for PSOC

Conclusions

This analysis suggests that oral PARPi therapy significantly improved survival benefits with an acceptable adverse effect profile.